Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04766892 · ClinicalTrials.gov registry record · Phase 2
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04766892 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 30 participants.
The verdict
NCT04766892, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and elevation of NT-proBNP with or without elevation of cTnT. Data from this study will inform future study designs of mavacamten in patients with HFpEF.
Interventions
- DRUG mavacamten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2024-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04766892
The ClinicalTrials.gov registry entry for NCT04766892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mavacamten is the first listed.
NCT04766892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04766892 about?
NCT04766892 is a clinical study titled "A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT". This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and elevation of NT-proBNP with or without elevation of cTnT. Data from this stud...
What is the current status of trial NCT04766892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-03-30. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT04766892?
The interventions under investigation include: mavacamten (DRUG).
Who is sponsoring clinical trial NCT04766892?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.